Asia Pacific Pharmaceutical Drug Delivery Market worth $687.9 million by 2031
The report "Asia Pacific Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Auto Injectors), Implantable, Transmucosal, Nasal, Syringes], Application [Cancer, Diabetes], Care Setting [Hospital, Home Care]—Global Forecast to 2031" is projected to grow from USD 479.7 million in 2026 and to reach USD 687.9 million by 2031, at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period.
Browse 210 market data Tables and 45 Figures spread through 245 Pages and in-depth TOC on "Asia Pacific Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Auto Injectors), Implantable, Transmucosal, Nasal, Syringes], Application [Cancer, Diabetes], Care Setting [Hospital, Home Care]—Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/asia-pacific-pharmaceutical-drug-delivery-market-123177497.html
The APAC pharmaceutical drug delivery market region experienced moderate growth, despite facing regional challenges and imbalances. However, the rising rates of chronic illnesses, the adoption of biologics and biosimilars, and a rapid transition towards more advanced drug-delivery devices and technologies drive market growth. Healthcare spending and government emphasis on immunization and associated health services, as well as an increase in local capabilities within drug and device manufacturing and contract and development services, have also worked as additional factors. Nevertheless, regional regulatory readiness and price-conscious regional markets have acted as moderating factors.
Regional dynamics shape challenges that factor into the APAC pharmaceutical drug delivery market. Regulatory requirements vary significantly across countries, resulting in inconsistent approval timelines and complicating market entry for advanced delivery systems. Price-sensitive environments in emerging markets limit the adoption of premium technology, while the varied healthcare infrastructure makes access to sophisticated injectable or connected devices different. Furthermore, supply-chain pressures related to sterility, cold-chain management, and raw material gaps further exacerbate the challenges. Limited patient training and awareness in rural areas about the optimal use of home-care and self-administration solutions are also prevalent across the region.
“By route of administration, the injectable drug delivery segment has accounted for the largest market share in 2025.”
By route of administration, in the APAC pharmaceutical drug delivery market, the injectable drug delivery segment holds the largest share in 2025 due to the region’s rising use of biologics, biosimilars, vaccines, and chronic disease therapies that require parenteral administration. The growing burden of conditions such as diabetes, cancer, and autoimmune disorders has increased demand for subcutaneous and intravenous delivery solutions. Strong adoption of pre-fillable syringes, autoinjectors, infusion systems, and wearable injectors further reinforces this segment’s dominance. Additionally, expanding hospital infrastructure, government immunization initiatives, and the rapid growth of APAC-based CDMOs supporting injectable manufacturing contribute to its leading market position.
“The cancer segment is expected to account for the highest CAGR, by application, in the APAC pharmaceutical drug delivery market.”
Based on applications, the cancer application segment in the APAC region is projected to experience the highest growth rate from 2026 to 2031, driven by the rapidly increasing incidence of oncology cases across China, India, Japan, South Korea, and Southeast Asia. Rising adoption of targeted therapies, immunotherapies, and biologics, all of which require advanced drug delivery systems, is driving strong demand. Governments and healthcare systems are expanding oncology infrastructure, improving screening programs, and increasing access to innovative treatments. Additionally, growing investments in injectable formulations, sustained-release technologies, and combination delivery devices by regional pharmaceutical companies and CDMOs further accelerate the segment’s expansion in APAC.
“By facility of use, the hospitals segment has accounted for the largest market share in 2025.”
By facility of use, the hospital segment is expected to hold the largest share in 2025 in the APAC pharmaceutical drug delivery market, due to the region’s heavy reliance on hospital-based administration for injectables, infusion therapies, oncology treatments, and complex biologics. Hospitals across China, Japan, India, and Southeast Asia continue to expand their capacity, adopt advanced delivery technologies, and manage high patient volumes for both chronic and acute conditions. Government investment in tertiary care, cancer centers, and critical care infrastructure further strengthens hospital dominance. Additionally, hospitals serve as the primary setting for the safe administration, monitoring, and management of high-risk or specialized therapies, reinforcing their leading role in the APAC region.
Key Market Players
Some of the major players in the APAC pharmaceutical drug delivery market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Terumo Corporation (Japan), Becton, Dickinson and Company (US), Merck & Co., Inc. (US), B. Braun (Germany), Gerresheimer AG (Germany), Cipla (India), Eli Lilly and Company (US), Novartis (Switzerland), Biogen (US), Baxter International (US), West Pharmaceutical Services (US), Sun Pharmaceutical Industries (India), GlaxoSmithKline (UK).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Asia Pacific Pharmaceutical Drug Delivery Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
